The Netherlands, 4 February 2013
Nordic Immunological Laboratories BV acquired the assets of MUbio Holding BV.
Pivotal Scientific represented Nordic Immunological in their acquisition process. We started by creating a long list and a short list of potential target companies (learn about list generation here). After narrowing down the options, we conducted comprehensive commercial due diligence (CDD), negotiated the sale price, and provided ongoing support throughout the entire process, ensuring a successful acquisition of MUbio Holding BV.
Nordic will continue to develop and manufacture high-quality MUbio research antibody reagents in the same facilities and with the same key personnel as before, all according to strict ISO 9001 quality guidelines.
CEO Ronald Rutten declared that the merger of the assets of MUbio along with the activities of Nordic will lead to a broad product portfolio of over 3,000 different antibodies, state of the art R&D, production and logistics facilities and synergy in distribution channels.
CSO Prof Frans Ramaekers added that to extend its product range of antibodies and diagnostic applications, Nordic/MUbio is continuously in close contact with different academic institutions, research groups and commercial partners to select additional opportunities.
